Mark J. Newman
Chief Scientific OfficerDr. Mark J. Newman, Ph.D. has been the Chief Scientific Officer of GeoVax Labs, Inc. since August 25, 2020 and served as its Vice President of Research and Development since January 2010 until 2013, worked for the GeoVax Labs on a half-time basis until March 2022. Dr. Newman joined the GeoVax Labs, Inc. in January 2010. Dr. Newman served as a Vice President of Research and Development of Geovax, Inc. Dr. Newman was responsible for developing GeoVax's therapeutic HIV vaccine initiative and broadening the GeoVax pipeline. He founded NewMark Diagnostics in 2016. Dr. Newman served as Vice President of Research and Development of PaxVax, Inc. Dr. Newman served as the Senior Vice President of Research and General Manager of Pharmexa-Epimmune of Pharmexa A/S. He joined Pharmexa in 2006 and has biotechnology R&D experience. Dr. Newman served in senior scientific management roles at Epimmune (San Diego), Vaxcel (Atlanta), Apollon (Philadelphia) and Cambridge Biotech (Boston) where he directed research, preclinical development and early stage clinical testing of DNA vaccines and several vaccine adjuvants. He served as Vice President for Research and Development of Epimmune Inc. since September 2003 and served as its Assistant Secretary. Dr. Newman served as Vice President for Infectious Disease Program of Epimmune Inc. from March 1999 to September 2003. Dr. Newman served as Vice President, Infectious Diseases of IDM Pharma, Inc. Prior to Epimmune, Dr. Newman served as Vice President of Research and Development of Vaxcel, Inc., from January 1995 to March 1999. Prior to Vaxcel, Dr. Newman he was an Associate Vice President of Research and Development for Apollon, Inc. Dr. Newman served as Senior Director of Cambridge Biotech Corporation. He is widely published in peer review publications and holds 10 U.S. patents. Dr. Newman holds one European patent, all related to vaccine technologies. Dr. Newman has co-authored more than 100 scientific papers, reviews and book chapters during his professional career. Dr. Newman has also been awarded multiple USA government and foundation grants and contracts to support his research in the field of vaccines. Dr. Newman completed of post-doctoral training at Cornell University (New York), worked with the National Cancer Institute, National Institutes of Health (Maryland) and served as a member of the Louisiana State University faculty. Dr. Newman holds a dual B.Sc and M.Sc. degree in Agriculture and Pre-Veterinary Medicine from the Ohio State University and earned his Ph.D. in Immunology at the John Curtin School for Medical Research, The Australian National University, Canberra.
Positions
- Company NameGeoVax Labs, Inc.Stock CodeGOVXPositionChief Scientific OfficerColleagues
- TOTyler O’BrienInterim CEO & Chairman of the Board
- ASAnna SkowronChief Financial Officer
- TOThomas O’BrienVice President of Quality Systems & Compliance
- JWJeffrey WelchHead of Process Development & Manufacturing Operations
- RTRobert T. McNallyIndependent Director
- DADavid Alan DoddDirector
- TLTeresa LambeInfectious Disease & Vaccine Scientific Advisory Board Member
- LTLance TurtleInfectious Disease & Vaccine Scientific Advisory Board Member
